Zebra Capital Management’s XBiotech XBIT Stock Holding History

Zebra Capital Management’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-12,588	Closed	-$235K	–	287
2019 Q4	$235K	Buy	+12,588	New	+$162K	0.21%	205

Other funds holding XBIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Zebra Capital Management's XBIT Position: Q1 2020 in Review

Zebra Capital Management sold out of XBiotech (XBIT) in Q1 2020, closing a stake of 12,588 shares — an estimated $235K sold.

Zebra Capital Management first reported a position in XBIT in Q4 2019 and held it in 1 quarter. The position peaked at $235K in Q4 2019. 60 funds tracked by Wall St. Rank hold XBIT as of Q1 2020.

Zebra Capital Management reported no remaining XBiotech position as of Q1 2020 after selling out during the quarter.
Zebra Capital Management sold 12,588 XBiotech shares in Q1 2020, an estimated $235K.
Zebra Capital Management first reported a position in XBiotech in Q4 2019 and held it in 1 quarter.
Zebra Capital Management's XBiotech position peaked at $235K in Q4 2019.
60 funds tracked by Wall St. Rank held XBiotech as of Q1 2020.

Based on Zebra Capital Management's 13F filing for Q1 2020, filed 15 May 2020.